The Procter Gamble Company

Procter & Gamble Pharmaceuticals, Inc.

David Edward Portlock

Song Liu

Schwe Fang Pong

Randy Stuart Muth

Gilles Yves Genain

Jean-Jacques Koenig

Jacques De Rostolan

Benjamin Eric Blass

Lawrence Joseph Wilson

Paul Michael Dybas

Roland Norman Johnson

Min Li

The subject invention involves compounds having structure (I): wherein each R1 is independently alkyl, aryl, or heterocycle; each R2, R4, R7, and R8 is independently hydrogen or other substituent; A is aryl or heterocycle; and pharmaceutically acceptable forms thereof. The subject invention also involves pharmaceutical compositions containing such compounds, and methods for treating or preventing diseases or disorders using such compounds.

N-(1-phenylethyl)-5-phenyl-imidazole-2-amine compounds, their compositions and uses

Imidazo-containing heterocyclic compounds, their compositions and uses

Imidazo-benzazepine compounds, their compositions and uses

The subject invention involves processes for making 1-aminohydantoin compounds using a solid support resin, comprising the following steps; (a) preparing a resin-bound protected &agr;-hydrazinyl ester; (1) by reacting the resin with an &agr;-bromo carboxylic acid, then with a protected hydrazine; or (2) by reacting the resin with a protected &agr;-hydrazinyl carboxylic acid; (b) preparing a resin-bound imine by removing the blocking group from the hydrazinyl moiety, then reacting the unprotected hydrazinyl moiety with an aldehyde or ketone; (c) preparing a resin-bound secondary urea: (1) by reacting the imine with p-nitrophenylchloroformate or trisphosgene, then with a primary amine; or (2) by reacting the imine with an isocyanate, and (d) preparing the 1-aminohydantoin compound by removing the secondary urea from the resin and cyclizing it.

Solid phase synthesis of 1-aminohydantoins

The subject invention involves compounds having the structure: wherein the C.sub..alpha. --N.sub..beta. and C.sub.5 -C.sub.6 bonds are independently single or double bonds, R1 is selected from alkyl, aryl, and heterocycle; R2-R13 are independently selected from hydrogen and other substituents; and pharmaceutically-acceptable salts thereof. The subject invention also involves pharmaceutical compositions containing such compounds, and methods for treating or preventing diseases and disorders using such compounds.

Imidazo-isoquinoline compounds, their compositions and uses

The present invention relates to new 14-aminosteroids, pharmaceutical compositions containing the new compounds and methods of treatment for humans or other mammals afflicted with congestive heart failure.

Oligosaccharide-containing 14 aminosteroid compounds and novel

The present invention relates to a method for making a compound of the structure: ##STR1## comprising the steps: (a) adding 6-deoxy-.alpha.-L-mannopyranosyl bromide, 2,3,4-tri-O-benzoate; DMSO; a base, selected from the group including tertiary amines, amidines, bicarbonates, carbonates, heteroaryl amine, and a solvent, hydrocarbons, esters, and ethers, in a slurry heated to 50.degree.-150.degree. C.;

Deoxy and oxygen-substituted sugar-containing 14-aminosteroid compounds

Disclosed are 14-aminosteroid compounds, including pharmaceutically acceptable acid salts and esters thereof, useful in treating individuals afflicted with congestive heart failure, which compounds have the general formula: ##STR1## wherein R.sub.3 is a deoxy or oxygen-substituted monosaccharide sugar residue and R.sub.1, R.sub.2 and R.sub.4 are various other substituents as defined herein.

Growing community of inventors

Maineville, OH, United States of America

David Edward Portlock